Key Highlights
•
A new MRI technique called susceptibility map-weighted imaging (SMwI) can accurately identify early Parkinson’s disease by enhancing a specific signal in a brain area called the substantia nigra. This finding is significant because it offers a practical fallback method for diagnosis using standard MRI scans when the dedicated version isn’t available, potentially improving early detection rates.
Source →
•
A survey of primary care patients found that after a brief education, 85% were willing to take a blood test for Alzheimer’s disease biomarkers if their doctor recommended it. This highlights a strong patient acceptance for simpler, more accessible testing methods, which could help integrate early Alzheimer’s detection into routine healthcare.
Source →
•
In rats, caffeine’s stimulating and aversive effects involve the brain’s α1-adrenergic receptor, a specific type of target for neurotransmitters. This discovery helps explain how caffeine works in the brain at a molecular level, which is crucial for understanding its widespread effects and potential interactions with other substances.
Source →
•
UK experts have published guidelines for the appropriate use of lecanemab, a new Alzheimer’s drug that clears amyloid plaques, over a year after its regulatory approval. This delay underscores the significant practical challenges in implementing such advanced, resource-intensive treatments within national healthcare systems.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
